Flowflex News & Product Updates

Stay up to date with Flowflex news, counterfeit notices, and product updates for COVID-19 and Flu A/B home tests.

Flowflex Plus COVID-19 and Flu A/B Home Test New Shelf-life Extension

Since the launch of its Flowflex Plus COVID-19 and Flu A/B Home Test, ACON Laboratories, Inc. has continued testing for product stability to extend the shelf-life. These results have been shared with the FDA. We are pleased to announce that the request to extend the Flowflex Plus COVID-19 and Flu A/B Home Test shelf-life from 15 months to 24 months, when stored at 36-86°F (2-30°C), has been granted. The Flowflex Plus COVID-19 and Flu A/B Home Test has an expiration date that is extended by 9 months. Look up the new expiration date using the lot number printed on the test kit box. Future shelf-life expiration date extensions will be communicated as they become available. If you have questions, please

Read More »

Flowflex® Plus COVID-19 + Flu A/B Home Test Receives FDA 510(k) Clearance

SAN DIEGO, CA., May 12, 2025 – ACON Laboratories, Inc., a leading global medical device manufacturer, announced today that its Flowflex® Plus COVID-19 + Flu A/B Home Test has received 510(k) clearance from the U.S. Food & Drug Administration (FDA). The Flowflex Plus COVID-19 + Flu A/B Home Test (K250377) is an over-the-counter (OTC) rapid antigen test that can be administered in the comfort and privacy of consumers’ homes. This version of the test will continue to be manufactured domestically in ACON’s state-of-the-art San Diego, CA facility. The Flowflex Plus COVID-19 and Flu A/B Home Test received Emergency Use Authorization (EUA) in July 2024, as a lateral flow immunoassay intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens.

Read More »

Public Notice Of Counterfeit Flowflex® COVID-19 Test Kits

ACON Laboratories, Inc. has become aware of counterfeit Flowflex COVID-19 Antigen Home Test kits displaying Lot number COV3090017 which are being illegally sold in the United States and Puerto Rico by unauthorized distributors. Although these counterfeit test kits appear to display an authentic Flowflex COVID-19 Antigen Home Test Lot number, these counterfeit test kits were not manufactured, imported, or distributed by ACON Laboratories. Counterfeit test kits displaying Lot number COV3090017 may be distinguished by examining the front of the kit box. On the counterfeit COV3090017 kit boxes, the sides of the illustrated tube do not extend into the teal. On authentic kit boxes, the sides of the illustrated tube extend into the teal and stop at the edge of the

Read More »

Public Notice Of Counterfeit Flowflex® COVID-19 Test Kits

ACON Laboratories, Inc. has become aware of counterfeit Flowflex COVID-19 Antigen Home Test kits displaying Lot number COV3090005 which are being illegally sold in the United States and Puerto Rico by unauthorized distributors. Although these counterfeit test kits appear to display an authentic Flowflex COVID-19 Antigen Home Test Lot number, these counterfeit test kits were not manufactured, imported, or distributed by ACON Laboratories. Counterfeit tests that display Lot number COV3090005 often produce invalid results (no Control line). The performance of these counterfeit tests has not been established and there is concern about the risk of inaccurate results when people use these unauthorized tests. Additionally, the 2D-datamatrix printed on the counterfeit test cassettes has been found to scan for invalid Lot

Read More »

Public Notice Of Counterfeit Flowflex® COVID-19 Test Kits

ACON Laboratories, Inc. has become aware of counterfeit Flowflex COVID-19 Antigen Home Test kits displaying Lot number COV3060007 which are being illegally sold in the United States by unauthorized distributors. Although these counterfeit test kits appear to display an authentic Flowflex COVID-19 Antigen Home Test Lot number, these counterfeit test kits were not manufactured, imported, or distributed by ACON Laboratories. These counterfeit test kits may be identified by mismatched Lot numbers on the test kit box label and test cassette pouch. These counterfeit test cassettes display a different Lot number on the test cassette pouch than the Lot number COV3060007 printed on the kit box label sticker on the outside of the test kit box. Additionally, these counterfeit test cassettes

Read More »

Flowflex® Plus COVID-19 and Flu A/B Home Test Receives FDA EUA

SAN DIEGO, CA., July 29, 2024 – ACON Laboratories, Inc., a leading global medical device manufacturer for 25 years, announced today that its Flowflex® Plus COVID-19 and Flu A/B Home Test has been authorized for emergency use by the U.S. Food and Drug Administration. The new Flowflex Plus COVID-19 and Flu A/B Home Test is a lateral flow immunoassay intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens. This test is authorized for non-prescription home use with self-collected anterior nares nasal swab specimens from individuals aged 14 years or older, or with adult-collected anterior nasal swab specimens from individuals two (2) years or older. This test is only authorized for individuals with signs

Read More »

Statement On The Omicron BA.2.86 And JN.1 Variants

ACON Laboratories, Inc. has been continuously monitoring the emergence of SARS-CoV-2 variants. According to the Centers for Disease Control and Prevention (CDC) COVID Data Tracker, the Omicron variant remains the dominant variant circulating in the United States. Among the new Omicron variants, BA.2.86 and JN.1 are currently the fastest-growing variants in the United States. Based on the study results from testing live clinical samples or virus samples of variants, the Flowflex® COVID-19 Antigen Home Test can reliably detect the Omicron B.1.1.529, BA.1, BA.2, BA.2.12.1, BA.2.3, BA.2.75.5, XBB, BA.4, BA.4.6, BA.5, BA.5.5, BQ.1, BQ.1.1, BQ.1.3, BQ.1.16, BF.5 and BF.7 variants with various nucleocapsid protein mutations, including many defining mutations for the Omicron variants. Therefore, our test has demonstrated adequate sensitivity against

Read More »

ACON Receives FDA 510(k) Clearance for Flowflex® COVID-19 Test; Will be Manufactured in San Diego

SAN DIEGO, CA, November 9, 2023 – ACON Laboratories, Inc. is proud to announce that the U.S. Food & Drug Administration (FDA) has granted 510(k) marketing clearance for the Flowflex® COVID-19 Antigen Home Test. This is the first FDA 510(k) for an over-the-counter (OTC) rapid antigen test for SARS-CoV-2, the virus which causes COVID-19. The 510(k) version of the Flowflex COVID-19 Antigen Home Test will also be produced domestically, in ACON Laboratories’ new 97,000 square foot San Diego manufacturing facility. The 510(k) cleared Flowflex COVID-19 Antigen Home Test is indicated for use only by symptomatic individuals within the first six days after symptom onset. An initial negative result must be followed by retesting between 48 and 72 hours after the

Read More »

Recall Issued by the Philadelphia Department of Public Health for Counterfeit Flowflex COVID-19 Tests

ACON Laboratories, Inc. is aware of the announcement by the Philadelphia Department of Public Health of a recall of certain at-home COVID-19 tests on September 9, 2023, and actively working with them and the FDA to conduct further investigation. The Lot number of concern “COV2110012” is not an authentic lot number of the Flowflex® COVID-19 Home Test manufactured by ACON Laboratories. This is not a manufacturer recall, as these are counterfeit tests that were not manufactured, imported, or distributed by ACON. Consumers should take precautions to avoid purchasing or using Flowflex tests marked with Lot# COV2110012. These counterfeit tests have not been authorized, cleared, or approved by the FDA for distribution or use in the United States. The performance of

Read More »

STATEMENT ON THE OMICRON EG.5 and FL.1.5.1 VARIANT

ACON Laboratories, Inc. has been continuously monitoring the emergence of SARS-CoV-2 variants. According to the Centers for Disease Control and Prevention (CDC) COVID Data Tracker, the Omicron variant remains the dominant variant circulating in the United States, among the new Omicron variants, XBB.1.9.1.1.5.1 (FL.1.5.1) and XBB.1.9.2.5 (EG.5) represent the highest portion of new COVID-19 infections nationwide. We have clinically verified that the Flowflex® COVID-19 Antigen Home Test can reliably detect the Omicron BA.1, BA.2, BA.4, BA.5 and BQ.1.1 variants with various nucleocapsid protein mutations, including many defining mutations for the Omicron variants. Therefore, our test has demonstrated broad sensitivity against a wide range of Omicron subvariants. While we have not tested the live clinical Omicron XBB subvariant samples, the GISAID

Read More »
Back To Top